Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Clovis Oncology stock logo
CLVS
Clovis Oncology
$0.43
$0.08
$3.32
$11.60M0.248.88 million shs1.16 million shs
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
$0.00
$0.00
$0.00
$0.02
$9K0.7912,688 shs900 shs
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
$1.36
+7.1%
$1.21
$0.66
$1.55
$288.67M1.861.45 million shs1.57 million shs
Organigram Global Inc. stock logo
OGI
Organigram Global
$1.44
+0.7%
$1.32
$0.85
$2.08
$191.53M1.36663,397 shs781,915 shs
7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Clovis Oncology stock logo
CLVS
Clovis Oncology
0.00%0.00%0.00%0.00%0.00%
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
0.00%0.00%0.00%0.00%+150.00%
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
+7.09%+12.40%+2.26%+75.03%+13.33%
Organigram Global Inc. stock logo
OGI
Organigram Global
+0.70%+4.35%+4.35%+49.04%-8.28%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Clovis Oncology stock logo
CLVS
Clovis Oncology
N/AN/AN/AN/AN/AN/AN/AN/A
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
N/AN/AN/AN/AN/AN/AN/AN/A
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
3.7634 of 5 stars
3.51.00.04.72.01.70.0
Organigram Global Inc. stock logo
OGI
Organigram Global
0.9625 of 5 stars
0.01.00.00.02.40.02.5
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Clovis Oncology stock logo
CLVS
Clovis Oncology
0.00
N/AN/AN/A
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
0.00
N/AN/AN/A
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
3.00
Buy$7.33439.22% Upside
Organigram Global Inc. stock logo
OGI
Organigram Global
3.00
BuyN/AN/A

Current Analyst Ratings Breakdown

Latest CLVS, OGI, GOSS, and EVLO Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
5/16/2025
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$7.00 ➝ $8.00
5/16/2025
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$4.00 ➝ $4.00
4/17/2025
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$8.00 ➝ $7.00
(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Clovis Oncology stock logo
CLVS
Clovis Oncology
$148.76M0.00N/AN/A($2.15) per share0.00
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
N/AN/AN/AN/AN/AN/A
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
$114.70M2.70N/AN/A$0.13 per share10.46
Organigram Global Inc. stock logo
OGI
Organigram Global
$194.09M0.99N/AN/A$2.07 per share0.70
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Clovis Oncology stock logo
CLVS
Clovis Oncology
-$264.52M-$1.83N/AN/AN/A-189.37%N/A-57.78%N/A
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
-$114.53MN/A0.00N/AN/AN/AN/AN/A
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
-$56.53M-$0.23N/AN/AN/A-41.12%-128.98%-15.52%8/11/2025 (Estimated)
Organigram Global Inc. stock logo
OGI
Organigram Global
-$33.39M$0.1014.40N/AN/A8.05%-5.93%-4.39%8/12/2025 (Estimated)

Latest CLVS, OGI, GOSS, and EVLO Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
-$0.18-$0.16+$0.02-$0.16$3.95 million$9.89 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Clovis Oncology stock logo
CLVS
Clovis Oncology
N/AN/AN/AN/AN/A
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
N/AN/AN/AN/AN/A
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
N/AN/AN/AN/AN/A
Organigram Global Inc. stock logo
OGI
Organigram Global
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Clovis Oncology stock logo
CLVS
Clovis Oncology
N/A
0.14
0.12
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
N/AN/AN/A
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
6.70
5.71
5.71
Organigram Global Inc. stock logo
OGI
Organigram Global
N/A
3.42
1.90

Institutional Ownership

CompanyInstitutional Ownership
Clovis Oncology stock logo
CLVS
Clovis Oncology
24.53%
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
0.31%
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
81.23%
Organigram Global Inc. stock logo
OGI
Organigram Global
34.63%

Insider Ownership

CompanyInsider Ownership
Clovis Oncology stock logo
CLVS
Clovis Oncology
4.40%
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
1.02%
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
6.70%
Organigram Global Inc. stock logo
OGI
Organigram Global
0.09%
CompanyEmployeesShares OutstandingFree FloatOptionable
Clovis Oncology stock logo
CLVS
Clovis Oncology
N/A144.96 million138.58 millionOptionable
Evelo Biosciences, Inc. stock logo
EVLO
Evelo Biosciences
12018.98 million18.79 millionNo Data
Gossamer Bio, Inc. stock logo
GOSS
Gossamer Bio
180227.30 million212.07 millionOptionable
Organigram Global Inc. stock logo
OGI
Organigram Global
860133.94 million133.82 millionOptionable

Recent News About These Companies

OGI Organigram Global Inc. - Seeking Alpha
Organigram Global Inc. (OGI.TO)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Clovis Oncology stock logo

Clovis Oncology NASDAQ:CLVS

Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca. As of 4/6/18, Rubraca® (rucaparib) is also approved by the FDA for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. FDA granted regular approval for Rubraca in this second, broader and earlier-line indication on a priority review timeline based on positive data from the phase 3 ARIEL3 clinical trial. Biomarker testing is not required for patients to be prescribed Rubraca in this maintenance treatment indication.

Evelo Biosciences stock logo

Evelo Biosciences NASDAQ:EVLO

$0.0005 0.00 (0.00%)
As of 07/9/2025 02:32 PM Eastern

Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriais; and is in Phase 2 clinical trial for the treatment of atopic dermatitis. The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Gossamer Bio stock logo

Gossamer Bio NASDAQ:GOSS

$1.36 +0.09 (+7.09%)
Closing price 07/9/2025 04:00 PM Eastern
Extended Trading
$1.35 -0.01 (-0.74%)
As of 04:39 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. Gossamer Bio, Inc. was incorporated in 2015 and is headquartered in San Diego, California.

Organigram Global stock logo

Organigram Global NASDAQ:OGI

$1.44 +0.01 (+0.70%)
Closing price 07/9/2025 04:00 PM Eastern
Extended Trading
$1.44 0.00 (0.00%)
As of 07/9/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Organigram Holdings Inc., through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including whole flower, milled flower, pre-rolls, infused pre-rolls, vapes, gummies, and concentrates for medical retailers; adult use recreational cannabis under the SHRED, Holy Mountain, Big Bag O' Buds, Monjour, Trailblazer, SHRED'ems, Edison Cannabis Co., Edison JOLTS, Tremblant, and Laurentian brands. The company also engages in the wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative-based products to retailers and wholesalers for adult-use recreational cannabis. It sells its products through online, as well as consumer channels. The company was incorporated in 2010 and is headquartered in Toronto, Canada.